SHENZHEN LIFOTRONIC TECHNOLOGY CO., LTD. Shenzhen Lifotronic Technology Co., Ltd. Stock
Equities
688389
CNE100005WZ5
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.1 CNY | +0.84% |
|
+0.90% | -15.15% |
| Sales 2024 * | 1.44B 199M | Sales 2025 * | 1.88B 259M | Capitalization | 8.18B 1.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 423M 58.42M | Net income 2025 * | 557M 76.92M | EV / Sales 2024 * | 5.68 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.36 x |
| P/E ratio 2024 * |
19.4
x | P/E ratio 2025 * |
14.7
x | Employees | 1,481 |
| Yield 2024 * |
1.73% | Yield 2025 * |
1.81% | Free-Float | 45.72% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.84% | ||
| 1 week | +0.90% | ||
| 1 month | -0.88% | ||
| 3 months | +2.47% | ||
| 6 months | -21.98% | ||
| Current year | -15.15% |
1 week
18.45
19.33
1 month
18.4521.10
Current year
14.0022.70
1 year
14.0026.00
3 years
12.0232.35
5 years
12.0240.96
10 years
12.0240.96
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Long Hu
CEO | Chief Executive Officer | 55 | 13-12-31 |
Min Liu
CHM | Chairman | 55 | 07-12-31 |
Hong Wang
DFI | Director of Finance/CFO | 58 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Long Hu
CEO | Chief Executive Officer | 55 | 13-12-31 |
Xian Cheng Liu
FOU | Founder | 56 | 08-01-15 |
Ying Zeng
BRD | Director/Board Member | 55 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 19.1 | +0.84% | 1,645,308 |
| 24-05-30 | 18.94 | -0.42% | 1,290,091 |
| 24-05-29 | 19.02 | +0.37% | 1,483,364 |
| 24-05-28 | 18.95 | -0.32% | 2,131,160 |
| 24-05-27 | 19.01 | +0.42% | 3,336,626 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
Shenzhen Lifotronic Technology Co Ltd is a China-based company mainly engaged in the research, development, manufacturing and marketing of medical devices. The Company focuses on the development and technological innovation of treatment and rehabilitation equipment, in vitro diagnostic equipment and supporting detection reagents. The Company's products mainly include wound and skin treatment products, perioperative and intensive care products, pain and rehabilitation treatment products and in vitro diagnostic products. The Company mainly conducts its businesses in domestic and overseas markets.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
19.1
CNY
Average target price
23.86
CNY
Spread / Average Target
+24.95%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.15% | 1.13B | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B | |
| -7.56% | 1.8B |
- Stock Market
- Equities
- 688389 Stock
